Pexiganan
Based on 1 publication(s) in Google Scholar
Pexiganan (MSI 78) is an orally active antimicrobial peptide with broad-spectrum bactericidal. Pexiganan disrupts bacterial cell membranes, induces peptidoglycan damage and cell lysis. Pexiganan TFA can be used for the research of bacterial infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.18%
- CAS. Nr.: 147664-63-9
- Formel: C122H210N32O22
- Molecular Weight:2477.17
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-P1222
LL-37, humanAntimicrobial Peptide -
HY-P0270
Magainin 2Antimicrobial Peptide -
HY-13629
EtoposideTopoisomerase II Inhibitor -
HY-13740
ResiquimodTLR7/8 Agonist -
HY-136278
DETA NONOateNO Donor -
HY-D1783
MitoTracker Deep Red FMRed Fluorescent Dye -
HY-P0233
MelittinPLA2 Activator -
HY-105048
OmigananCationic antimicrobial peptide -
HY-P0092
Cecropin BCytochrome P450 Inhibitor -
HY-P5712
Gramicidin SAntibiotic -
HY-P99044
SabatolimabTIM-3 Antibody -
HY-P3512
IsegananAntimicrobial Peptide
Publications Citing Use of MedChemExpress (MCE) Pexiganan
More
Biologische Aktivität
Beschreibung
In Vitro
Pexiganan (1-256 µg/mL; 24 h) exhibits comparable bactericidal activity against planktonic Staphylococcus aureus Z25.2, Pseudomonas aeruginosa Z25.1, and their dual-species cultures[1].
Pexiganan (1-256 µg/mL; 24 h) is more effective at inhibiting and eradicating Staphylococcus aureus Z25.2 biofilms than Pseudomonas aeruginosa Z25.1 or dual-species biofilms[1].
Pexiganan (7-35 μM) binds to purified bovine type I collagen with a dissociation constant of 34.01 μM[3].
Pexiganan (5-80 μg/mL; overnight) inhibits the growth of Pseudomonas aeruginosa and Staphylococcus aureus[3].
Pexiganan (40 μg/mL; 0-60 min) rapidly reduces viable counts of Pseudomonas aeruginosa (ATCC27853) and Staphylococcus aureus (ATCC29213) over 60 min, with complete elimination of P. aeruginosa by 60 min[3].
Pexiganan (10-50 μg/mL) exhibits no cytotoxicity toward rat fibroblast cells in in vitro MTT assays[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pexiganan (1 mg/kg; i.p.; single dose) reduces lethality, and intra-abdominal bacterial counts in E. coli-induced septic shock in male Wistar rats[4].
Pexiganan (1 mg/kg; i.p.; single dose) reduces lethality, and intra-abdominal bacterial counts in in cecal ligation and puncture-induced septic shock in male Wistar rats[4].
Pexiganan (1 mg/kg; i.p.; single dose) is well-tolerated with no detectable adverse effects or physiological changes in healthy male Wistar rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar rats (adult male, 200-300 g, E. coli O111:B4 LPS (HY-D1056A1)-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced plasma endotoxin levels to ≤0.015 EU/mL.
Reduced plasma TNF-α levels to 0.26 ng/mL.
-
Animal Model:Wistar rats (adult male, 200-300 g, E. coli-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Resulted in 32.3% lethality, 5/15 positive blood cultures, and intra-abdominal bacterial counts of 6.0 × 103 CFU/mL.
-
Animal Model:Wistar rats (adult male, 200-300 g, cecal ligation and puncture-induced septic shock)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:When administered immediately after surgery, resulted in 32.3% lethality, 5/15 positive blood cultures, and intra-abdominal bacterial counts of 6.9 × 103 CFU/mL.
When administered immediately after surgery, produced significant reductions in plasma endotoxin and TNF-α levels compared to control and β-lactam-treated groups.
When administered 360 minutes after surgery, resulted in 40.0% lethality, 6/15 positive blood cultures, and intra-abdominal bacterial counts of 6.0 × 104 CFU/mL.
When administered 360 minutes after surgery, produced significant reductions in plasma endotoxin and TNF-α levels compared to control and β-lactam-treated groups.
-
Animal Model:Wistar rats (adult male, 200-300 g)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose
-
Result:Showed no drug-related adverse effects.
Caused no changes in measured physiological parameters including leukocyte count, serum creatinine, rectal temperature, pulse, blood pressure, breathing rate, and oxygenation.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 147664-63-9
-
Appearance Solid
-
Molecular Weight 2477.17
-
Formel C122H210N32O22
-
Color White to off-white
-
Synonyms
MSI 78 free base
-
Sequence Shortening
GIGKFLKKAKKFGKAFVKILKK-NH2
-
Structure Classification
-
Initial Source
the skin of the African clawed frog
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (40.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (40.37 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Gomes D, et al. Pexiganan in Combination with Nisin to Control Polymicrobial Diabetic Foot Infections. Antibiotics (Basel). 2020;9(3):128. Published 2020 Mar 20. [Content Brief]
[2]. Ghazvini K, et al. Sustain-release lipid-liquid crystal formulations of pexiganan against Helicobacter pylori infection: in vitro evaluation in C57BL/6 mice. BMC Pharmacol Toxicol. 2024;25(1):9. Published 2024 Jan 11. [Content Brief]
[3]. Gopinath D, et al. Pexiganan-incorporated collagen matrices for infected wound-healing processes in rat. J Biomed Mater Res A. 2005;73(3):320-331. [Content Brief]
[4]. Giacometti A, et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides. 2005;26(2):207-216. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 0.4037 mL | 2.0184 mL | 4.0369 mL | 10.0922 mL |
| 5 mM | 0.0807 mL | 0.4037 mL | 0.8074 mL | 2.0184 mL | |
| 10 mM | 0.0404 mL | 0.2018 mL | 0.4037 mL | 1.0092 mL | |
| 15 mM | 0.0269 mL | 0.1346 mL | 0.2691 mL | 0.6728 mL | |
| 20 mM | 0.0202 mL | 0.1009 mL | 0.2018 mL | 0.5046 mL | |
| 25 mM | 0.0161 mL | 0.0807 mL | 0.1615 mL | 0.4037 mL | |
| 30 mM | 0.0135 mL | 0.0673 mL | 0.1346 mL | 0.3364 mL | |
| 40 mM | 0.0101 mL | 0.0505 mL | 0.1009 mL | 0.2523 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pexiganan Related Classifications
HY-105088 Related Classifications
Powered by Bioz
Keywords